Appeal No.2001-1258 Page 2
Application No. 08/413,805
4. A pharmaceutically acceptable composition which comparisies as
active ingredient, a pharmaceutically effective amount of
immunogenic GA733-2E consisting of the amino acid sequence of
SEQ ID NO: 2 in pharmaceutically acceptable carrier.
The examiner relies on the following references:
European Patent Application
Bumol 0 326 423 Aug. 2, 1989
Hussey et al. (Hussey), “A soluble CD4 protein selectively inhibits HIV replication
and syncytium formation cells,” Nature, Vol. 331, pp. 79-81 (1988)
Johnson et al. (Johnson), ”Synthesis of soluble myelin-associated glycoprotein in
insect and mammalian cells,” Gene, Vol. 77, pp. 287-296 (1989)
Szala et al. (Szala), ”Molecular cloning of cDNA for the carcinoma-associated
antigen GA733-2,” Proc. Natl. Acad. Sci., Vol. 87, pp.3542-3546 (1990)
Claims 1, 3, 4, 6, 7, 9, 10, 19-21, 24, 25, 30, and 31 stand rejected under
35 U.S.C. § 103 as obvious in view of the combined disclosures of Szala, Bumol,
Hussey, and Johnson.
We affirm.
Background
“GA733-2 is a 40 kDa human cell surface glycoprotein antigen that is
associated with carcinomas of various origins. Its biological function remains
unknown. Hydrophobicity analysis of the protein sequence predicted by cDNA
has suggested that the GA733-2 antigen is a type I membrane protein, i.e., it
possesses signal peptide, extracellular domain, trans-membrane domain and
intracellular anchor.” Specification, page 2. The specification discloses a
truncated variant of the GA733-2 antigen, designated GA733-2E, that consists
of the signal peptide and extracellular domains of the full-length protein.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007